CD123 AML targeting by chimeric antigen Receptors,A novel magic bullet for AML therapeutics? CD123 AML通过靶向嵌合抗原受体,一种新的灵丹妙药AML疗法? Abstract: Chimeric antigenreceptor (CAR) modified cells have emerged as powerful tools for controllingleukemias. we recently showed thatanti-CD123 CAR-expressing cytokine-induced killer t cell treatment is aneffective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML)cells. here, we discuss how this genetically modifiedcell-based strategy could be relevant to the field of AML therapeutics. 摘要: 嵌合抗原受体(CAR)的改进型的T细胞已成为控制白血病强大的工具。我们最近发现,抗CD123 CAR表达的细胞因子诱导的杀伤T细胞治疗是消除急性髓系白血病(AML)细胞的有效免疫治疗的方法。
|